Cherney, David Z.I.

Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial

Heerspink, H. J. L., Birkenfeld, A. L., Cherney, D. Z. I., Colhoun, H. M., Ji, L., Mathieu, C., Groop, P.-H., Pratley, R. E., Rosas, S. E., Rossing, P., et al. (2023) · Diabetes Research and Clinical Practice

Chronic Kidney Disease and DiabetesAcute Kidney Injury Research

Cited by 63

Cardiac autonomic neuropathy and early progressive renal decline in patients with nonmacroalbuminuric type 1 diabetes

Orlov, S., Cherney, D. Z. I., Pop-Busui, R., Lovblom, L. E., Ficociello, L. H., Smiles, A. M., Warram, J. H., Krolewski, A. S., & Perkins, B. A. (2015) · Clinical Journal of the American Society of Nephrology

Chronic Kidney Disease and DiabetesDiabetes Management and Research

Cited by 57

Tirzepatide Associated With Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1–5 Clinical Trials

Apperloo, E. M., Tuttle, K. R., Pavo, I., Haupt, A., Taylor, R., Wiese, R. J., Hemmingway, A., Cherney, D. Z. I., Sattar, N., & Heerspink, H. J. L. (2025) · Diabetes Care

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 53

Effects of tirzepatide versus insulin glargine on cystatin C-based kidney function: a SURPASS-4 post hoc analysis

Heerspink, H. J. L., Sattar, N., Pavo, I., Haupt, A., Duffin, K. L., Yang, Z., Wiese, R. J., Wilson, J. M., Hemmingway, A., Cherney, D. Z. I., et al. (2023) · Diabetes Care

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 53

Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function

van Bommel, E. J. M., Lytvyn, Y., Perkins, B. A., Soleymanlou, N., Fagan, N. M., Koitka-Weber, A., Joles, J. A., Cherney, D. Z. I., & van Raalte, D. H. (2020) · Kidney International

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 47

Serum glycated albumin predicts all-cause mortality in dialysis patients with diabetes mellitus: meta-analysis and systematic review of a predictive biomarker

Copur, S., Siriopol, D., Afsar, B., Comert, M. C., Uzunkopru, G., Sag, A. A., Ortiz, A., Covic, A., van Raalte, D. H., Cherney, D. Z., et al. (2021) · Acta Diabetologica

Dialysis and Renal Disease ManagementAdvanced Glycation End Products research

Cited by 38

Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial

Dagogo-Jack, S., Pratley, R. E., Cherney, D. Z. I., McGuire, D. K., Cosentino, F., Shih, W. J., Liu, J., Frederich, R., Mancuso, J. P., Raji, A., et al. (2021) · BMJ Open Diabetes Research & Care

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 37

The effect of oral contraceptives on the nitric oxide system and renal function

Cherney, D. Z. I., Scholey, J. W., Cattran, D. C., Kang, A. K., Zimpelmann, J., Kennedy, C., Lai, V., Burns, K. D., & Miller, J. A. (2007) · American Journal of Physiology-Renal Physiology

Renin-Angiotensin System StudiesNitric Oxide and Endothelin Effects

Cited by 33

SGLT2 Inhibitors and Risk for Hyperkalemia Among Individuals Receiving RAAS Inhibitors

Wing, S., Ray, J. G., Yau, K., Jeyakumar, N., Abdullah, S., Luo, B., Cherney, D. Z. I., Harel, Z., Hundemer, G. L., Mavrakanas, T. A., et al. (2025) · JAMA Internal Medicine

Potassium and Related DisordersDiabetes Treatment and Management

Cited by 29

Prevalence of Insulin Pump Therapy and Its Association with Measures of Glycemic Control: Results from the Canadian Study of Longevity in Type 1 Diabetes

Boulet, G., Halpern, E. M., Lovblom, L. E., Weisman, A., Bai, J.-W., Eldelekli, D., Keenan, H. A., Brent, M. H., Paul, N., Bril, V., et al. (2016) · Diabetes Technology & Therapeutics

Diabetes Management and ResearchDiabetes Management and Education

Cited by 26

What have we learned about renal protection from the cardiovascular outcome trials and observational analyses with SGLT2 inhibitors?

Sridhar, V. S., Rahman, H. U., & Cherney, D. Z. I. (2020) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 24

Kidney Parameters with Tirzepatide in Obesity with or without Type 2 Diabetes

Heerspink, H. J. L., Friedman, A. N., Bjornstad, P., van Raalte, D. H., Cherney, D., Cao, D., Garcia-Pérez, L.-E., Stefanski, A., Turfanda, I., Bunck, M. C., et al. (2025) · Journal of the American Society of Nephrology

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 20

Advancing kidney protection in type 1 diabetes: insights from emerging therapies in type 2 diabetes and chronic kidney disease

Kugathasan, L., Aronson, Y., Sridhar, V. S., Ni, H., Ouimet, J.-P., Limonte, C. P., Sarma, S., & Cherney, D. Z. I. (2025) · Expert Review of Clinical Immunology

Chronic Kidney Disease and DiabetesDiabetes Management and Research

Cited by 9

Capillary ketone level and future ketoacidosis risk in patients with type 1 diabetes using sodium-glucose cotransporter inhibitors

Bapat, P., Dhaliwal, S., Song, C., Zhang, Y., Scarr, D., Bakhsh, A., Budhram, D., Verhoeff, N. J., Weisman, A., Fralick, M., et al. (2025) · Diabetes Care

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 4